1. Home
  2. HYMC vs ANIP Comparison

HYMC vs ANIP Comparison

Compare HYMC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hycroft Mining Holding Corporation

HYMC

Hycroft Mining Holding Corporation

HOLD

Current Price

$21.24

Market Cap

1.9B

ML Signal

HOLD

Logo ANI Pharmaceuticals Inc.

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$76.95

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYMC
ANIP
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2018
1999

Fundamental Metrics

Financial Performance
Metric
HYMC
ANIP
Price
$21.24
$76.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
1.8M
360.3K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
64.26
419.23
EPS
N/A
2.32
Revenue
N/A
$206,547,000.00
Revenue This Year
N/A
$21.01
Revenue Next Year
N/A
$17.59
P/E Ratio
N/A
$33.58
Revenue Growth
N/A
2.47
52 Week Low
$5.93
$69.58
52 Week High
$58.73
$96.99

Technical Indicators

Market Signals
Indicator
HYMC
ANIP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
HYMC
ANIP

About HYMC Hycroft Mining Holding Corporation

Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: